Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · May 2022 · 1 min read
In brief
In brief
Multi-institutional study of 262 pediatric patients with hepatocellular neoplasms reveals distinct prognostic patterns across histologic subtypes. Conventional HCC showed worse outcomes than fibrolamellar carcinoma, with mortality predicted by tumor resectability, multifocality, and PRETEXT stage IV disease.
Written by the GCMD Library team from the article.
Statements in this article
Pediatric hepatocellular neoplasms were categorized into three histologic subtypes: conventional HCC with or without underlying liver disease, fibrolamellar carcinoma, and hepatoblastoma with HCC features.
Among 262 children with hepatocellular neoplasms, institutional histologic review identified 110 conventional HCCs (42%), 119 fibrolamellar carcinomas (45%), and 33 hepatoblastomas with HCC features (12%).
Of 110 conventional HCC cases, 69 occurred in normal background liver, 34 in inflammatory or cirrhotic liver, and 7 had unknown background liver status.
Fibrolamellar carcinoma showed increased lymph node involvement compared to other hepatocellular neoplasm subtypes.
Conventional HCC presented at higher stage compared to other hepatocellular neoplasm subtypes.
Conventional HCC histology was associated with increased mortality (hazard ratio 1.63, P = .038).
Elevated α-fetoprotein was associated with increased mortality (hazard ratio 3.1, P = .014).
Multifocal disease was associated with increased mortality (hazard ratio 2.4, P < .001).
PRETEXT stage IV disease was associated with increased mortality (hazard ratio 5.76, P < .001).
Multivariate analysis identified conventional HCC versus fibrolamellar carcinoma as an independent predictor of increased mortality (hazard ratio 2.2, P = .004).
Unresectable tumors were independently associated with increased mortality (hazard ratio 3.4, P < .001).
Disease-free status at any point during treatment predicted survival in pediatric hepatocellular neoplasms.